Aventis Divests Azmacort For $200 Mil.; Kos To Back Relaunch With 500 Reps
Executive Summary
Kos Pharmaceuticals will relaunch Azmacort with a 490-representative sales force following its $200 mil. purchase of the inhaled corticosteroid from Aventis
You may also be interested in...
Kos Will Re-Launch Teveten And Cardizem LA In June Following Biovail Deal
Kos will re-launch Biovail's three cardiovascular products in June following the addition of 150 Biovail reps to its sales team
Kos Will Re-Launch Teveten And Cardizem LA In June Following Biovail Deal
Kos will re-launch Biovail's three cardiovascular products in June following the addition of 150 Biovail reps to its sales team
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid